Variables associated with circuit life span in critically ill patients undergoing continuous renal replacement therapy: A prospective observational study

ASAIO Journal

Volumn 58, Issue 1, 2012, Pages 46-50

  Zhang, Zhongheng ^a   Ni, Hongying ^a   Lu, Baolong ^a  

^a JINHUA MUNICIPAL CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTI-COAGULATION; BODY TEMPERATURE; CIRCUIT FUNCTIONS; COX REGRESSION; CRITICALLY-ILL PATIENTS; FILTER LIFE; HEMOFILTRATION; LIFE SPAN; LOWER BODY; OBSERVATIONAL STUDY; PH VALUE; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPIES; STANDARD DEVIATION; SURVIVAL TIME;

CALCIUM; COAGULATION; INTENSIVE CARE UNITS; IONIZATION; PATIENT MONITORING; PATIENT TREATMENT; PH; PHYSIOLOGY; PLATELETS; POLYSACCHARIDES;

ELECTRIC NETWORK ANALYSIS;

CALCIUM; HEPARIN; ION;

ADULT; AGED; ARTICLE; BLOOD; BODY TEMPERATURE; CRITICAL ILLNESS; FEMALE; HEMOFILTRATION; HUMAN; INTENSIVE CARE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PH; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; THROMBOCYTE COUNT; TIME;

ADULT; AGED; BODY TEMPERATURE; CALCIUM; CRITICAL ILLNESS; FEMALE; HEMOFILTRATION; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; INTENSIVE CARE; IONS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; TIME FACTORS;

EID: 84855362585     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31823fdf20     Document Type: Article

References (22)

1. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous is not continuous: The incidence and impact of circuit "downtime" on uraemic control during continuous venovenous haemofiltration. Intensive Care Med 29: 575-578, 2003. (Pubitemid 36523673)
2. Monti G, Herrera M, Kindgen-Milles D, et al; Dose Response Multicentre International Collaborative Initiative Scientific Committee: The DOse REsponse Multicentre International Collaborative Initiative (DO-RE-MI). Contrib Nephrol 156: 434-443, 2007.
3. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 356: 26-30, 2000. (Pubitemid 30416991)
4. Holt AW, Bierer P, Bersten AD, Bury LK, Vedig AE: Continuous renal replacement therapy in critically ill patients: Monitoring circuit function. Anaesth Intensive Care 24: 423-429, 1996. (Pubitemid 126449233)
5. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Predilution vs. post-dilution during continuous veno-venous hemofiltration: Impact on filter life and azotemic control. Nephron Clin Pract 94: c94-c98, 2003.
6. del Castillo J, López-Herce J, Cidoncha E, et al: Circuit life span in critically ill children on continuous renal replacement treatment: A prospective observational evaluation study. Crit Care 12: R93, 2008.
7. Baldwin I, Bellomo R, Koch B: Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med 30: 2074-2079, 2004. (Pubitemid 40022324)
8. Kim IB, Fealy N, Baldwin I, Bellomo R: Premature circuit clotting due to likely mechanical failure during continuous renal replacement therapy. Blood Purif 30: 79-83, 2010.
9. Kim IB, Fealy N, Baldwin I, Bellomo R: Insertion side, body position and circuit life during continuous renal replacement therapy with femoral vein access. Blood Purif 31: 42-46, 2011.
10. Ricci Z, Ronco C, Bachetoni A, et al: Solute removal during continuous renal replacement therapy in critically ill patients: Convection versus diffusion. Crit Care 10: R67, 2006.
11. Krouzecky A, Chvojka J, Sykora R, et al: Regional cooling of the extracorporeal blood circuit: A novel anticoagulation approach for renal replacement therapy? Intensive Care Med 35 364-370 2009
12. Martini WZ: Coagulopathy by hypothermia and acidosis: Mechanisms of thrombin generation and fibrinogen availability. J Trauma 67: 202-8; discussion 208, 2009.
13. Aslam AF, Aslam AK, Vasavada BC, Khan IA: Hypothermia: Evaluation, electrocardiographic manifestations, and management. Am J Med 119: 297-301, 2006.
14. Kheirabadi BS, Delgado AV, Dubick MA, et al: In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures. J Trauma 63: 1079-1086, 2007. (Pubitemid 350098530)
15. Viuff D, Lauritzen B, Pusateri AE, Andersen S, Rojkjaer R, Johansson PI: Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven). Br J Anaesth 101: 324-331, 2008.
16. Darlington DN, Kheirabadi BS, Delgado AV, Scherer MR, Martini WZ, Dubick MA: Coagulation changes to systemic acidosis and bicarbonate correction in swine. J Trauma 71: 1271-1277, 2011.
17. Holt AW, Bierer P, Glover P, Plummer JL, Bersten AD: Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med 28: 1649-1655, 2002. (Pubitemid 36002517)
18. Hetzel GR, Schmitz M, Wissing H, et al: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: A prospective randomized multicentre trial. Nephrol Dial Transplant 26: 232-239, 2011.
19. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 67: 2361-2367, 2005. (Pubitemid 41623398)
20. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intensive Care Med 30: 260-265, 2004. (Pubitemid 38253417)
21. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR: Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based? Intensive Care Med 32 188-202 2006 (Pubitemid 43251138)
22. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl): 188S-203S, 2004. (Pubitemid 39297954)